fbpx
QQQ
+ 0.00
366.48
+ 0%
DIA
+ 0.01
350.81
+ 0%
SPY
-0.06
440.71
-0.01%
TLT
+ 0.00
148.82
+ 0%
GLD
-0.02
171.19
-0.01%

Wells Fargo Shares Takeaways From Canopy Growth CEO's New York Presentation

December 12, 2018 3:56 pm
Share to Linkedin Share to Twitter Share to Facebook Share to Print License More

On Dec. 11, the Consumer Analyst Group of New York hosted a group luncheon where Canopy Growth Corp. (NYSE:CGC) CEO Bruce Linton presented.

Wells Fargo analysts attended the luncheon and presented their main takeaways. Overall, the analysts said they are optimistic about the company's prospects and its relationship with Constellation Brands, Inc. (NYSE:STZ)

Wells Fargo's Main Takeaways

Wells Fargo analysts did not provide their outlook on Canopy Growth's stock, but cited a number of positive aspects from Linton's presentation.

Canopy Growth is expected to see more revenue, as its supply constraints were mainly caused by government bottlenecks, analyst Bonnie Herzog said in a note. In addition, the company has adequate production assets in Canada, with 4.3 million square feet of production facilities and 1.7 million pending, she said.

As s it completes its investments in Canada, CGC will continue to increase its presence in international markets and introduce more products.

Cannabis investors can't miss the Benzinga Cannabis Capital Conference, the No. 1 networking event for institutional capital and the leading cannabis companies. Secure your tickets here before they run out.

Regarding the collaboration with Constellation Brands, which acquired a 38-percent stake in Canopy Growth, Herzog noted the upcoming release of CBD-infused beverages the companies are developing. (See her track record here.) 

Canopy plans to launch a scalable, calorie-free and transparent beverage with a quick onset and long shelf life, the analyst said.

Canopy plans to begin trials for a cannabidiol, or CBD, sleep aid in January, according to Wells Fargo. 

Canopy To Enter US Market

Wells Fargo believes Canopy Growth is well-positioned to enter the U.S. market following the descheduling of hemp in the pending 2018 US Farm Bill and the transfer of its supervision to the Department of Agriculture from the Drug Enforcement Administration.

Herzog noted the FDA's role in hemp regulation "given the emergent nature of the category and clear lack of longitudinal data."

Related Links:

Aphria Tops List Of Hot Stocks Among Short Sellers

10 Reasons To Attend Benzinga's 2019 Cannabis Capital Conference

For the latest in financial news, exclusive stories, memes follow Benzinga on Twitter, Facebook & Instagram. For the best interviews, stock market talk & videos, subscribe to Benzinga Podcasts and our YouTube channel.


Related Articles

Cannabis Analyst Reviews Sluggish Canadian Data: 'MSOs Will Outperform Again'

Hifyre Canadian cannabis sales data for the month of December is in, and the numbers suggest the Canadian retail cannabis market remains sluggish heading into 2021. read more

3 Reasons Marijuana Stocks Are Soaring

Cannabis stocks have been red-hot following Tuesday’s election. The skyrocketing marijuana group has been led by Aurora Cannabis Inc. (NYSE: ACB), which is up 135% in the past two days alone. read more

Canopy Growth Analyst Sees Increasing Cannabis Market Share, Little Stock Upside

Canopy Growth Corp. (NYSE: CGC) shares traded higher on Tuesday after the company held a virtual meeting on Monday and reassured investors that the company is leading the cannabis group in three major long-term growth markets. read more

Aurora Cannabis Analysts On Pros, Cons Of Entry Into US CBD Market

Aurora Cannabis Inc (NYSE: ACB) shares are on a roll yet again, this time in reaction to its announcement that it is entering the U.S. read more